Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
11,898 total articles
Genco Shipping & Trading Ltd.'s chairman, CEO and president John C. Wobensmith sold 39,244 shares of GNK common stock on February 23, 2026 for about $928,513 while simultaneously taking delivery of 78,486 shares from vested restricted stock units. Separately, Diana Shipping Inc. has submitted a non-binding cash proposal to buy Genco for $20.60 per …
Genco Shipping & Trading Ltd.'s Chief Financial Officer, Peter George Allen, completed sales of common stock totaling 13,315 shares for $315,005 on February 23, 2026, while also acquiring shares through option exercises and RSU vesting. The same day, Genco's board declined Diana Shipping Inc.'s attempt to nominate six director candidates as part of…
Genco Shipping & Trading Ltd.'s Chief Commercial Officer Jesper Christensen sold 18,450 shares of company stock on February 23, 2026 for roughly $436,527 while also receiving 38,438 shares through restricted stock unit vesting. The transaction coincides with a broader corporate dispute after Genco rejected Diana Shipping Inc.'s board nomination eff…
Ardelyx director David Mott reported a purchase of 333,333 shares on February 20, 2026, at a weighted average price of $5.839 per share, representing a total outlay of $1,946,331. The acquisition leaves Mott with 3,302,918 shares outright. The transaction occurred amid a recent near-15% slide in the stock and follows corporate updates including rev…
Pulse Biosciences Chief Commercial Officer Kevin Patrick Danahy sold 5,000 shares of common stock on February 18, 2026, for $118,200 under a pre-arranged Rule 10b5-1 plan and simultaneously exercised options to acquire 5,000 shares at $1.53. The move comes amid recent analyst coverage, an FDA investigational device exemption approval for a cardiac …
John E. Bishop, Ardelyx's Chief Technical Operations Officer, sold 3,179 shares on February 20, 2026, in an automated transaction to cover withholding taxes tied to restricted stock unit vesting. The sales generated $18,586 at prices between $5.7003 and $5.865. The trade arrives amid a near 15% decline in Ardelyx stock over the prior week, even as …
Ardelyx Senior Vice President and Chief Accounting Officer Joseph James Reilly sold 4,991 shares on February 20, 2026, to satisfy tax withholding tied to vested restricted stock units. The trades, executed under a pre-arranged plan, generated $29,180 and leave Reilly with 151,790 shares directly held. The moves come amid recent share-price weakness…
Avantor director Gregory T. Lucier purchased 50,000 shares of Avantor, Inc. common stock on February 19, 2026, in transactions totaling $458,000. The purchases occurred at prices between $9.06 and $9.25 per share, with an average execution price reported at $9.16. The buy comes while the stock trades close to its 52-week low and after fourth-quarte…
Laura A. Williams, Ardelyx's Chief Patient Officer and interim Chief Medical Officer, sold 8,176 shares of common stock on February 20, 2026, in two transactions to cover withholding taxes tied to the vesting of restricted stock units. The trades, executed at prices between $5.7138 and $5.865, totaled $47,803. After the sale Williams holds 436,082 …
Ardelyx Chief Financial Officer Susan Hohenleitner sold 2,033 shares of common stock on February 20, 2026 to satisfy withholding tax obligations tied to restricted stock units. The transactions totaled $11,886. The company also provided forward-looking product revenue guidance for fiscal 2026, initiated a Phase 3 IBSRELA study, and received a U.S. …
Mike Kelliher, Chief Business Officer of Ardelyx, sold 9,695 shares of the company's common stock on February 20, 2026, in three transactions totaling $56,099 to satisfy withholding tax obligations tied to vested restricted stock units. The share price during those trades ranged from $5.705 to $5.865; the stock is trading at $5.75 and has fallen ne…
On February 20, 2026, Brady James Parker, Chief Human Resources Officer at Ardelyx, Inc. (NASDAQ: ARDX), sold 2,543 shares of common stock in two transactions to satisfy withholding tax obligations tied to vested restricted stock units. The trades totaled $14,867. The company concurrently reported several operational and regulatory developments, in…
Biodesix Chief Financial Officer Robin Harper Cowie sold 535 shares of company stock on February 23, 2026, for roughly $6,834, at a weighted average price of $12.7756. The transaction followed an options exercise on February 20, 2026, that yielded 1,469 shares via restricted stock units. The stock has risen 87.79% year-to-date even as the company w…
Kieran O’Kane, Chief Commercial Officer at Biodesix Inc. (NASDAQ: BDSX), sold 535 shares on Feb. 23, 2026 to cover tax obligations tied to recently vested restricted stock units. The transactions follow an option exercise on Feb. 20, 2026 that converted 1,469 RSUs into shares. Biodesix reported preliminary 2025 results showing revenue growth and EB…
Biodesix INC Chief Development Officer Gary Anthony Pestano sold 556 shares on February 23, 2026, for roughly $7,103 at a weighted average price of $12.7756. The transaction occurred as the stock traded close to an InvestingPro Fair Value of $13.12 and after preliminary results showed revenue growth and EBITDA profitability for 2025. Pestano had ex…
Ameris Bancorp Chief Strategy Officer James A. LaHaise executed a sale of 6,641 shares on February 19, 2026, for $550,738, while also receiving 14,910 shares from a performance stock unit grant. The sale represented withholding to satisfy tax obligations tied to the grant. Following the transactions, LaHaise holds 111,470 shares. Ameris Bancorp's s…
Adam Eltoukhy, Samsara Inc's Executive Vice President, Chief Legal Officer and Secretary, sold 4,688 shares of Class A common stock on February 20, 2026, for roughly $125,611 at an average price of $26.6981 per share. The trades took place while the stock is trading close to its 52-week low and amid fresh analyst coverage and company-reported safet…
Entegris INC (NASDAQ: ENTG) Senior Vice President and General Counsel Joseph Colella completed a series of equity transactions on February 19-20, 2026, including an open-market sale of 1,580 shares for roughly $207,754 and a separate disposition of 2,574 shares to cover tax obligations. On February 19 he also received 4,850 shares tied to the settl…
Olivier Blachier, Entegris' senior vice president and chief strategy officer, executed planned and tax-related sales of company stock in mid-February 2026 while also receiving performance-settled shares. The transactions occurred as Entegris traded close to its 52-week high and after the company reported a fourth-quarter earnings beat that prompted…
Michael Eugene Lee, Senior Vice President and Chief Regulatory Officer of Five Star Bancorp, disposed of 1,200 shares of the company's common stock on February 20, 2026, in a transaction valued at $47,160. The sale leaves Lee with 35,272 shares, some of which were granted under the Five Star Bancorp 2021 Equity Incentive Plan. Separately, Five Star…
A Ridgepost Capital director acquired 10,000 shares of the company's Class A common stock on February 19, 2026, for $86,500. The purchase came as the stock traded near its 52-week low; the transaction followed the company's rebranding from P10 to Ridgepost Capital, its new RPC ticker listing, and expansion into the Dubai International Financial Cen…
Dino A. Rossi, a director at Krystal Biotech, sold 18,950 shares of common stock on February 19, 2026, in two transactions totaling $4.95 million, and on the same day exercised options to acquire 18,950 shares at $8.79. The company reported fourth-quarter 2025 results that exceeded analyst forecasts for both EPS and revenue. The stock has risen 82%…
USANA Health Sciences Chief Legal Officer Joshua Foukas sold 4,461 shares on February 20, 2026, at $21.345 per share, netting about $95,220 and leaving him with no direct holdings, according to a Form 4 filing. The company recently adjusted its fiscal 2025 net sales target to roughly $925 million and issued an initial revenue range of $925 million …
Eric Sprott and an affiliated Ontario entity purchased 150,000 Class A shares of Hycroft Mining Holding Corp (HYMC) on February 20, 2026, at $42.05 per share, a transaction valued at $6,307,500. The acquisition increases their combined holdings to 36,903,704 shares and is disclosed amid a surge in Hycroft stock and a substantive update to the compa…
A Timken Co director sold 10,000 shares on February 19, 2026, for roughly $1.06 million as the stock approached its 52-week peak. The transaction, reported on a Form 4, followed robust fourth-quarter results and recent analyst price-target revisions, while third-party analysis flags the stock as overvalued relative to its fair value.
